CAL101 for idiopathic pulmonary fibrosis

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 17 Dec 2024: Trial registered, NCT06736990
  2. 20 Jun 2025: Trial started, NCT06736990

The trials

NCT06736990: A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis

State
Under way
Phase
Phase 2
People
150 planned
Started
20 Jun 2025
Primary completion
Nov 2026
Arms
CAL101
Results
None posted
  1. 17 Dec 2024: Trial registered
  2. 20 Jun 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.